Daily Endocrinology Research Analysis
Analyzed 120 papers and selected 3 impactful papers.
Summary
Mechanistic work in beta-cell proteostasis maps BiP-centered chaperone assemblies that safeguard proinsulin folding, advancing targets for type 2 diabetes. Clinically, a meta-analysis shows hemithyroidectomy carries higher differentiated thyroid cancer recurrence than total thyroidectomy, and an agent-level network meta-analysis reinforces cardiovascular benefits of GLP-1–based therapies in type 2 diabetes.
Research Themes
- ER proteostasis and proinsulin folding mechanisms in beta cells
- Extent of thyroidectomy and recurrence risk in differentiated thyroid cancer
- Cardiovascular outcomes across GLP-1–based therapies in type 2 diabetes
Selected Articles
1. Coordinated expression and assembly of BiP, p58
Using a knock-in mouse enabling pulldown of endogenous islet BiP complexes, the authors map how BiP assembles with cochaperones (including p58) to manage proinsulin folding in the ER. The work clarifies ER chaperone network organization that prevents proinsulin misfolding implicated in β-cell stress in T2D.
Impact: Defines endogenous ER chaperone assemblies safeguarding proinsulin folding, introducing a powerful in vivo tool and mechanistic framework for β-cell proteostasis in T2D.
Clinical Implications: Mechanistic insight may inform strategies to pharmacologically boost ER folding capacity or chaperone-cochaperone function to restore β-cell health in T2D.
Key Findings
- Engineered mouse enabled efficient pulldown of endogenous β-cell BiP (GRP78) complexes with client proteins.
- BiP assembles into diverse multi-protein complexes, including with cochaperones such as p58, to manage proinsulin folding.
- Findings delineate a coordinated ER chaperone network that counters proinsulin misfolding linked to β-cell ER stress in T2D.
Methodological Strengths
- Genetically engineered in vivo system capturing endogenous BiP complexes without overexpression artifacts
- Direct biochemical mapping of chaperone–client assemblies in native islets
Limitations
- Translational relevance to human β cells and T2D requires validation
- Incomplete coverage of all ER chaperones/cochaperones and dynamic regulation in stress states
Future Directions: Validate chaperone complexes in human islets, define dynamic remodeling under metabolic stress, and test small molecules that enhance BiP-cochaperone function to improve proinsulin folding.
Proper proinsulin folding in the endoplasmic reticulum (ER) is prerequisite to producing bioactive insulin, and proinsulin misfolding causing β cell ER stress accompanies pancreatic β cell dysfunction in type 2 diabetes (T2D). How (and which) ER chaperones coordinate to prevent proinsulin misfolding is largely unknown other than an unspecified dependence on the hsp70 member, BiP. A genetically engineered mouse enables efficient, specific pulldown of endogenous islet β cell BiP (GRP78, the major HSP70 ER chaperone) in complexes with client proteins. We demonstrate that BiP assembles in various protein complexes (including cochaperones p58
2. The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.
Across 15 RCTs (97,173 participants), GLP-1–based therapies reduced all-cause and cardiovascular mortality and MACE vs placebo in pairwise analyses. Agent-level NMA suggested the most favorable MACE profiles for efpeglenatide, albiglutide, and injectable semaglutide, with mortality differences less distinct across agents.
Impact: Provides contemporary, agent-level cardiovascular comparisons for GLP-1–based therapies, informing selection beyond class effects in T2D.
Clinical Implications: Supports GLP-1–based therapies for cardiovascular risk reduction in T2D and highlights potential agent-level differences for MACE when individualizing therapy.
Key Findings
- Pairwise meta-analyses showed significant reductions in all-cause mortality, cardiovascular mortality, and MACE versus placebo.
- Network meta-analysis suggested efpeglenatide, albiglutide, and injectable semaglutide had the most favorable comparative MACE profiles.
- Non-fatal MI was reduced with albiglutide versus placebo; non-fatal stroke estimates were imprecise.
Methodological Strengths
- Hazard ratio–based agent-level network meta-analysis across randomized trials
- Large cumulative sample size with consistency checks via pairwise and network estimates
Limitations
- Indirect comparisons susceptible to between-trial heterogeneity and varying background care
- Imprecision for some outcomes (e.g., non-fatal stroke) and limited head-to-head evidence
Future Directions: Head-to-head cardiovascular outcome trials and real-world comparative effectiveness studies to confirm agent-level differences and optimize individualized therapy.
AIMS: To provide updated agent-level comparative estimates of GLP-1-based therapies for cardiovascular outcomes in adults with Type 2 diabetes mellitus (T2DM) using a hazard ratio (HR)-based systematic review and network meta-analysis (NMA). METHODS: PubMed, Cochrane Library and Scopus were searched through December 2025 for randomized controlled trials evaluating GLP-1-based therapies in adults with T2DM and reporting time-to-event cardiovascular outcomes. Pairwise meta-analyses and a frequentist random-effects NMA were performed for all-cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), non-fatal myocardial infarction (MI) and non-fatal stroke. RESULTS: Fifteen trials involving 97,173 participants were included. In pairwise placebo-controlled analyses, GLP-1-based therapies significantly reduced all-cause mortality, cardiovascular mortality and MACE. In the NMA, mortality estimates for several agents favoured benefit, although most comparisons were not statistically significant. For MACE, efpeglenatide, albiglutide and injectable semaglutide showed the most favourable comparative profiles. Albiglutide reduced non-fatal MI versus placebo, whereas non-fatal stroke estimates were imprecise. CONCLUSIONS: GLP-1-based therapies were associated with an overall favourable cardiovascular profile in T2DM. Pairwise analyses supported class-level benefit, whereas between-agent differences were more evident for MACE than for mortality outcomes in the NMA.
3. Recurrence Risk of Differentiated Thyroid Cancer Treated with Total or Hemithyroidectomy. Systematic Review and Meta-analysis.
Across 46 retrospective studies (98,604 patients), hemithyroidectomy was associated with higher DTC recurrence than total thyroidectomy (OR 1.56) with an absolute increase of ~3%. Heterogeneity was high, but pooled prevalence and risk difference consistently favored lower recurrence with total thyroidectomy.
Impact: Addresses a central surgical decision with large-scale evidence synthesis, informing initial operative strategy in DTC.
Clinical Implications: When oncologic safety is prioritized, total thyroidectomy may lower recurrence versus hemithyroidectomy; patient selection should integrate tumor risk, comorbidity, and patient preference while counseling on recurrence trade-offs.
Key Findings
- Pooled recurrence prevalence: 5.8% after total thyroidectomy vs 8.1% after hemithyroidectomy.
- Higher recurrence with hemithyroidectomy (OR 1.56; 95% CI 1.47–1.66).
- Absolute risk difference favored total thyroidectomy by approximately 3% (95% CI 3–4%), with substantial heterogeneity (I2 85–87%).
Methodological Strengths
- Comprehensive search with dual data extraction and random-effects pooling
- Very large aggregated sample enhancing precision of pooled estimates
Limitations
- All included studies were retrospective, with potential selection and confounding biases
- High heterogeneity (I2 > 80%) limits strength of causal inference
Future Directions: Prospective, risk-stratified cohorts and pragmatic trials to refine selection for hemithyroidectomy vs total thyroidectomy, incorporating molecular risk and patient-reported outcomes.
BACKGROUND: Differentiated thyroid carcinoma (DTC) is traditionally treated with total thyroidectomy (TT); however, hemithyroidectomy (HT) has been increasingly used. Previous analyses on DTC recurrence rate with HT and TT have yielded inconsistent results; this study aimed to bridge this gap. METHODS: Searches were conducted in PubMed/MEDLINE and Embase. Furthermore, references of previous systematic reviews were screened to extend the search until May 2025. Specific data of recurrence rate were independently extracted from the included studies by two observers and then pooled using a random-effects model. The primary endpoint was the risk difference (RD) in cancer recurrence rate between HT and TT. The secondary endpoints included recurrence prevalence (RP) for TT and HT, and odds ratio (OR) comparing HT with TT. RESULTS: 2556 papers were initially identified, and 46 retrospective studies were included. The overall quality of the studies was satisfactory. In total, 98,604 patients were treated with TT (n = 75,531) or HT (n = 23,073). The proportion meta-analyses revealed a pooled RP of 5.8% in TT and 8.1% in HT. The HT group had a significantly higher probability of DTC recurrence than the TT group (OR 1.56, 95% CI 1.47-1.66, I2 85%). The RD meta-analysis revealed that the recurrence rate was significantly higher in the HT group than in the TT group, by 3% (95% CI 3-4, I2 87%). CONCLUSIONS AND RELEVANCE: The DTC recurrence rate following HT is significantly higher than that observed following TT. Thyroid specialists should consider this finding when tailoring initial treatment strategies.